Shots:

• Pear Therapeutics launches Somryst as the first PDT intended for use in the treatment of patients with chronic insomnia aged > 22yrs. It addresses the issues of chronic insomnia by delivering (CBTi) approach that trains the brain and body to sleep
• In a study of ~1-400 adults with CI- PDT reduced the amount of time it took to fall asleep (45%)- reduced the amount of time spent awake at night (52%) and reduced severity of insomnia symptoms (45%) with continued improvement at 6 & 12 mos. post-treatment
• Somryst will be promoted via a fully virtual experience- combining telemedicine visits and PDT prescribing and dispensation via PearConnect

 ­ Ref: Pear therapeutics | Image: MobileHealthNews